What happened with XTNT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Xtant Medical Holdings, Inc. supplies surgeons with products for bone healing, spinal fixation, surgical repair and wound care. These include products made from donated human tissue, as well as implants and instruments used in spinal procedures. Product sales provide most of its revenue, and the United States is its main market. Independent commissioned agents help sell to healthcare providers, while stocking distributors buy products for resale; much of its spinal hardware revenue depends on these intermediaries.
The company also makes products under distributors’ names and licenses manufacturing and sales rights. Its SimpliMax agreement gives a distributor exclusive U.S. rights in exchange for royalties tied to sales. Reimbursement changes affecting SimpliMax and SimpliGraft took effect at the start of 2026, and the SimpliGraft supply agreement ended at the close of 2025. Xtant also sold its Coflex and CoFix assets and international hardware business to Companion Spine in late 2025.
Demand depends on insurers and government health programs covering the procedures that use its products. Providers often receive a bundled payment for a procedure rather than separate payment for the product, making the product’s cost important to their purchasing decisions. Production also depends on access to suitable donated human tissue and placentas.
Human-tissue rules shape how Xtant earns money: U.S. law prohibits selling transplant organs for valuable consideration but permits reasonable payments for specified services, which is how Xtant receives payment for its allograft bone activities. Its tissue products must meet FDA criteria to remain under the tissue-only regulatory pathway, and new devices or uses generally need FDA authorization before marketing.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Xtant’s near-term results hinge on skin-substitute reimbursement changes and replacing revenue lost through its hardware divestiture to Companion Spine, not just on spinal surgery demand.
Orthofix Medical and Xtant compete for spine surgeons’ adoption and hospitals’ purchases of spinal implants and bone-healing biologics used in fusion procedures. Orthofix’s Global Spine sales are the line to watch for this rivalry; the division accounted for 84% of its 2025 net sales.
Alphatec Holdings competes with Xtant to supply spine surgeons with fixation systems and biologics for spinal surgery. Watch surgeon adoption of Alphatec’s procedure-specific products, which the company identifies as a driver of future growth.
Globus Medical competes with Xtant for spinal surgery purchases through implantable fixation devices and biologics. Those products sit within Globus’s Musculoskeletal Solutions business, making that category more relevant to Xtant than its imaging, navigation and surgical robotics offerings.
Bioventus competes with Xtant’s bone-healing biologics by selling bone graft substitutes for orthopedic and spinal procedures. Its bone graft substitute business is the relevant sales line to watch, rather than its broader pain-treatment portfolio.
SI-BONE and Xtant compete to supply spine and pelvic surgeons with products that fix and fuse the sacroiliac joint. Adoption of SI-BONE’s iFuse products is a concrete measure to watch: more than 140,000 procedures had used them from their 2009 introduction through December 31, 2025.
Tenon Medical competes with Xtant’s products for sacroiliac conditions by selling joint-fusion systems to healthcare facilities through distributors and sales representatives. Watch sales of its Catamaran and SImmetry+ systems for competition in this specific part of Xtant’s market.
Integra LifeSciences competes with Xtant in surgical repair and chronic wound care, selling regenerative tissue and wound-repair products against Xtant’s collagen and amniotic tissue products.
Medtronic competes with Xtant to supply spinal implants and bone-healing biologics for spinal surgery, but these markets are only part of Medtronic’s diversified business. Its news on those products is more relevant to Xtant than results from unrelated businesses such as diabetes care.
Integra LifeSciences Holdings earningsIART
Integra LifeSciences’ report will show demand for surgical-repair and chronic-wound products, where its regenerative-tissue offerings compete with Xtant Medical’s collagen and amniotic-tissue products.
Watch sales of Integra LifeSciences’ relevant regenerative-tissue and wound-repair products. Stronger sales would indicate firmer demand in surgical repair and wound care, markets Xtant Medical also serves; weaker sales would point to a more difficult backdrop, not prove that Xtant’s own sales moved the same way.
Bioventus Inc. earningsBVS
Bioventus’s report will show sales of bone-graft substitutes, which compete with Xtant Medical’s bone-healing biologics for orthopedic and spinal procedures.
Focus on Bioventus’s bone-graft-substitute business, not its pain-treatment portfolio. Stronger sales would suggest firmer demand for these products in orthopedic and spinal procedures, a supportive backdrop for Xtant Medical’s bone-healing products; weaker sales would suggest softer category demand, but would not establish a change in Xtant’s sales or share.
Orthofix Medical Inc. earningsOFIX
Orthofix Medical’s report will show how its Global Spine sales are changing; its spinal implants and bone-healing biologics compete with Xtant Medical for surgeons and hospital purchases.
Watch Global Spine sales rather than mixing in Orthofix’s other businesses. Stronger sales would indicate demand for spinal implants and bone-healing products is firm, and that Xtant Medical faces stronger competition for surgeon adoption and hospital purchases; weaker sales would suggest less momentum in this shared market, not that Xtant has won those orders.
SI-BONE, Inc. earningsSIBN
SI-BONE’s report will show adoption of its iFuse products, which compete with Xtant Medical for surgeons and facility purchases in sacroiliac-joint fixation and fusion.
Watch iFuse adoption and related procedure use. Rising adoption would show more surgeons and patients choosing sacroiliac-joint fixation and fusion, and stronger competition for Xtant Medical in this product area; slower adoption would indicate less momentum in that niche, not an automatic gain in demand for Xtant.
Xtant Medical Holdings, Inc. earningsThis company
Xtant Medical’s report will show whether sales of its remaining products can support revenue and gross profit after reimbursement changes and the sale of part of its hardware business.
Read product revenue alongside gross margin, and note whether the figures still include sales tied to the divested Coflex and CoFix business or SimpliMax, which faces reimbursement changes. If product sales hold and margins remain firm without relying on those sources, the remaining business is absorbing the change; if either weakens, reimbursement pressure or the smaller portfolio is still weighing on operations.
